Skip to Content
CN
EN
Products
Applications
Services
Resources
Support
Analytical Chemistry
Cell Culture & Analysis
Chemistry & Biochemicals
Clinical & Diagnostics
Filtration
Greener Alternative Products
Industrial Microbiology
Lab Automation
Labware
Materials Science
Molecular Biology & Functional Genomics
mAbs Development & Manufacturing
mRNA Development & Manufacturing
Pharma & Biopharma Manufacturing
Protein Biology
Water Purification
Analytical Chemistry
Cell Culture & Analysis
Chemistry & Synthesis
Clinical & Diagnostics
Environmental & Cannabis Testing
Food & Beverage Testing & Manufacturing
Genomics
Materials Science & Engineering
Microbiological Testing
mAbs Development & Manufacturing
mRNA Development & Manufacturing
Pharma & Biopharma Manufacturing
Protein Biology
Research & Disease Areas
Water Purification
Contract Manufacturing
Contract Testing
Custom Products
Digital Solutions for Life Science
IVD Development & Manufacturing
Product Services
Support
Documents
Learning Center
New
Web Training
User Guide for Millipore Website Consolidation
Ordering Information
Customer Support
After-Sales Support
Technical Support
Process Solution Support
Contact Us
Get Site Smart
FAQ
Quality & Regulatory
Calculators & Apps
Webinars
Home
Search Results
Drug-induced burning mouth syndrome: a new clinico-pathological entity?
Drug-induced burning mouth syndrome: a new clinico-pathological entity?
The journal of headache and pain (2012-10-12)
Giulio Fortuna, Annamaria Pollio
PMID
23054064
MATERIALS
Product Number
Brand
Product Description
C0460000
Carbidopa, European Pharmacopoeia (EP) Reference Standard
Pricing
C1335
Sigma-Aldrich
S-(−)-Carbidopa, ≥98% (TLC), powder
Pricing
